-- クエストー・テクノロジー（QST.V）は月曜日、最高経営責任者（CEO）のオードリー・マスカレニャス氏が即日辞任したと発表した。 マスカレニャス氏の辞任理由は明らかにされていない。 同社によると、1999年にクエストーに入社し、2005年にCEOに就任したマスカレニャス氏は、同社を廃ガス燃焼分野における市場リーダーへと導き、国内外市場における強力なブランド認知度の構築に貢献した。 取締役会は、近いうちに完了する見込みの移行計画に取り組んでいる。移行期間中は、マイク・リンゼイ氏が暫定社長兼CEOを務める。 マスカレニャス氏は引き続き取締役を務め、ポール・ハイジンガ氏が会長に就任したと同社は発表した。 同社の株価は、トロント証券取引所ベンチャー市場で0.04ドル安の0.31ドルで取引を終えた。
Price: $0.30, Change: $-0.06, Percent Change: -15.71%
Easou Technology (HKG:2550) said it has subscribed to a $7.7 million wealth management product issued by Huatai International Financial Products, using idle proceeds from its earlier placings, according to a Friday Hong Kong bourse filing.Shares of the digital service firm were down over 1% in Monday's late-morning trade.The investment, guaranteed by Huatai International Financial, carries an annualized return of 1.07% to 5.83% over a term ending March 30, 2027.Easou said the move aims to enhance the utilization efficiency and returns on idle funds while maintaining liquidity.
SSY Group (HKG:2005) said it received Chinese regulatory approval to begin drug production and registration of its diltiazem hydrochloride in injection form, according to a Hong Kong bourse filing Monday.The drug is mainly used to treat a heart condition known as supraventricular tachycardia and the emergency treatment of abnormally high blood pressure during surgery.The firm's propranolol hydrochloride injection was also approved for production and registration by China's National Medical Products Administration.The product is mainly used to treat supraventricular tachyarrhythmias and ventricular arrhythmias.
Amplitude Energy (ASX:AEL) said Australian Retirement Trust raised its stake in the firm to 6.3% as of Friday from 5.1% as of April 2, according to a Monday Australian bourse filing.Australian Retirement Trust now holds nearly 19 million votes in the firm.